Patent ID: 7919261
Filing Date: 2011-04-05
Classification: A61P,C12Q,G01N

Abstract:
1. A method of predicting whether a patient presenting with an HDAC mediated cutaneous T-cell lymphoma is at risk of non-responsiveness to treatment with SAHA, comprising: detecting in malignant T cells from the patient the phosphorylation status of STAT-1 protein relative to the phosphorylation status of SAT-1 protein in malignant T cell from a subject presenting with an HDAC mediated cutaneous T-cell lymphoma that is responsive to treatment with SAHA, wherein higher levels of phosphorylation of STAT-1 protein in the patient sample as compared to the level of phosphorylation of STAT-1 protein in the subject presenting with HDAC mediated cutaneous T-cell lymphoma that is responsive to treatment with SAHA indicates the patient is non-responsive to treatment with SAHA.